Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Rosuvastatin calcium
All strengths: General benefit; same patient cost rules
Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ach-Rosuvastatin · DIN 02438917 · 5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ach-Rosuvastatin · DIN 02438917
Manufacturer: Accord Healthcare Inc.; listing date 2019-07-31
Health Canada: Marketed since 2019-05-23 · brand ACH-ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 5 MG · company Accord healthcare inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAch-Rosuvastatin: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1284). What the ministry pays, not the patient.
Ministry pays: $0.1284 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02438917)
Source record
DIN 02438917: Ach-Rosuvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600066; group id 308; item number 0674; lccId None; manufacturer id ACH
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1284; ministry $0.1284
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02438917
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92329
Interchangeable products
Apo-Rosuvastatin · DIN 02337975 · $0.1284
Auro-Rosuvastatin · DIN 02442574 · $0.1284
Bio-Rosuvastatin · DIN 02444968 · $0.1284
Co Rosuvastatin · DIN 02339765 · $0.1284
Crestor · DIN 02265540 · $0.1284
Jamp Rosuvastatin Calcium · DIN 02498332 · $0.1284
Jamp-Rosuvastatin · DIN 02391252 · $0.1284
M-Rosuvastatin · DIN 02496534 · $0.1284
Mar-Rosuvastatin · DIN 02413051 · $0.1284
Med-Rosuvastatin · DIN 02399164 · $0.1284
Mint-Rosuvastatin · DIN 02397781 · $0.1284
NRA-Rosuvastatin · DIN 02477483 · $0.1284
NRA-Rosuvastatin Tablets · DIN 02536595 · $0.1284
PMS-Rosuvastatin · DIN 02378523 · $0.1284
PRZ-Rosuvastatin · DIN 02505576 · $0.1284
Rosuvastatin · DIN 02405628 · $0.1284
Rosuvastatin · DIN 02411628 · $0.1284
Sandoz Rosuvastatin · DIN 02338726 · $0.1284
Taro-Rosuvastatin · DIN 02382644 · $0.1284
Teva-Rosuvastatin · DIN 02354608 · $0.1284
Shortage status: resolved shortage (ended September 19, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02438917
Shortage record checked October 6, 2026
Apo-Rosuvastatin · DIN 02337975 · 5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Rosuvastatin · DIN 02337975
Manufacturer: Apotex Inc.; listing date 2012-05-29
Health Canada: Marketed since 2012-04-02 · brand APO-ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 5 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Rosuvastatin: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1284). What the ministry pays, not the patient.
Ministry pays: $0.1284 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02337975)
Source record
DIN 02337975: Apo-Rosuvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600066; group id 308; item number 0674; lccId None; manufacturer id APX
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1284; ministry $0.1284
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02337975
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82362
Interchangeable products
Ach-Rosuvastatin · DIN 02438917 · $0.1284
Auro-Rosuvastatin · DIN 02442574 · $0.1284
Bio-Rosuvastatin · DIN 02444968 · $0.1284
Co Rosuvastatin · DIN 02339765 · $0.1284
Crestor · DIN 02265540 · $0.1284
Jamp Rosuvastatin Calcium · DIN 02498332 · $0.1284
Jamp-Rosuvastatin · DIN 02391252 · $0.1284
M-Rosuvastatin · DIN 02496534 · $0.1284
Mar-Rosuvastatin · DIN 02413051 · $0.1284
Med-Rosuvastatin · DIN 02399164 · $0.1284
Mint-Rosuvastatin · DIN 02397781 · $0.1284
NRA-Rosuvastatin · DIN 02477483 · $0.1284
NRA-Rosuvastatin Tablets · DIN 02536595 · $0.1284
PMS-Rosuvastatin · DIN 02378523 · $0.1284
PRZ-Rosuvastatin · DIN 02505576 · $0.1284
Rosuvastatin · DIN 02405628 · $0.1284
Rosuvastatin · DIN 02411628 · $0.1284
Sandoz Rosuvastatin · DIN 02338726 · $0.1284
Taro-Rosuvastatin · DIN 02382644 · $0.1284
Teva-Rosuvastatin · DIN 02354608 · $0.1284
Shortage status: active shortage (reported September 22, 2026, estimated to end November 13, 2026, last updated October 2, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02337975
Shortage record checked October 6, 2026
Auro-Rosuvastatin · DIN 02442574 · 5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Rosuvastatin · DIN 02442574
Manufacturer: Auro Pharma Inc.; listing date 2016-04-01
Health Canada: Marketed since 2015-11-30 · brand AURO-ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 5 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAuro-Rosuvastatin: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1284). What the ministry pays, not the patient.
Ministry pays: $0.1284 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02442574)
Source record
DIN 02442574: Auro-Rosuvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600066; group id 308; item number 0674; lccId None; manufacturer id AUR
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1284; ministry $0.1284
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02442574
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92691
Interchangeable products
Ach-Rosuvastatin · DIN 02438917 · $0.1284
Apo-Rosuvastatin · DIN 02337975 · $0.1284
Bio-Rosuvastatin · DIN 02444968 · $0.1284
Co Rosuvastatin · DIN 02339765 · $0.1284
Crestor · DIN 02265540 · $0.1284
Jamp Rosuvastatin Calcium · DIN 02498332 · $0.1284
Jamp-Rosuvastatin · DIN 02391252 · $0.1284
M-Rosuvastatin · DIN 02496534 · $0.1284
Mar-Rosuvastatin · DIN 02413051 · $0.1284
Med-Rosuvastatin · DIN 02399164 · $0.1284
Mint-Rosuvastatin · DIN 02397781 · $0.1284
NRA-Rosuvastatin · DIN 02477483 · $0.1284
NRA-Rosuvastatin Tablets · DIN 02536595 · $0.1284
PMS-Rosuvastatin · DIN 02378523 · $0.1284
PRZ-Rosuvastatin · DIN 02505576 · $0.1284
Rosuvastatin · DIN 02405628 · $0.1284
Rosuvastatin · DIN 02411628 · $0.1284
Sandoz Rosuvastatin · DIN 02338726 · $0.1284
Taro-Rosuvastatin · DIN 02382644 · $0.1284
Teva-Rosuvastatin · DIN 02354608 · $0.1284
Shortage status: resolved shortage (ended December 2, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02442574
Shortage record checked October 6, 2026
Bio-Rosuvastatin · DIN 02444968 · 5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Bio-Rosuvastatin · DIN 02444968
Manufacturer: Biomed Pharma; listing date 2026-09-29
Health Canada: Marketed since 2021-08-11 · brand BIO-ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 5 MG · company Biomed pharma · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordBio-Rosuvastatin: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1284). What the ministry pays, not the patient.
Ministry pays: $0.1284 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02444968)
Source record
DIN 02444968: Bio-Rosuvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600066; group id 308; item number 0674; lccId None; manufacturer id BMP
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1284; ministry $0.1284
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02444968
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93018
Interchangeable products
Ach-Rosuvastatin · DIN 02438917 · $0.1284
Apo-Rosuvastatin · DIN 02337975 · $0.1284
Auro-Rosuvastatin · DIN 02442574 · $0.1284
Co Rosuvastatin · DIN 02339765 · $0.1284
Crestor · DIN 02265540 · $0.1284
Jamp Rosuvastatin Calcium · DIN 02498332 · $0.1284
Jamp-Rosuvastatin · DIN 02391252 · $0.1284
M-Rosuvastatin · DIN 02496534 · $0.1284
Mar-Rosuvastatin · DIN 02413051 · $0.1284
Med-Rosuvastatin · DIN 02399164 · $0.1284
Mint-Rosuvastatin · DIN 02397781 · $0.1284
NRA-Rosuvastatin · DIN 02477483 · $0.1284
NRA-Rosuvastatin Tablets · DIN 02536595 · $0.1284
PMS-Rosuvastatin · DIN 02378523 · $0.1284
PRZ-Rosuvastatin · DIN 02505576 · $0.1284
Rosuvastatin · DIN 02405628 · $0.1284
Rosuvastatin · DIN 02411628 · $0.1284
Sandoz Rosuvastatin · DIN 02338726 · $0.1284
Taro-Rosuvastatin · DIN 02382644 · $0.1284
Teva-Rosuvastatin · DIN 02354608 · $0.1284
Shortage status: resolved shortage (ended January 30, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02444968
Shortage record checked October 6, 2026
Crestor · DIN 02265540 · 5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Savings card: innoviCares lists Crestor (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up.
(innovicares.ca ↗)Savings card: RxHelp ONE lists CRESTOR (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim.
(rxhelp.ca ↗)Limit of one Prescription Drug Card Program / Patient Financial Assistance Card from any adjudicator per DIN and claim submitted. The RxHelpONE card CANNOT be combined with any other card or offer. (Terms of Use)
(rxhelp.ca, September 10, 2026 ↗)1 brand, same coverage
Crestor · DIN 02265540
Manufacturer: AstraZeneca; listing date 2007-01-02
Health Canada: Marketed since 2005-03-18 · brand CRESTOR - 5MG · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 5 MG · company Astrazeneca canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMinistry pays: $0.1284 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02265540)
Source record
DIN 02265540: Crestor
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600066; group id 308; item number 0674; lccId None; manufacturer id AZC
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.5177; ministry $0.1284
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02265540
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75100
Interchangeable products
Ach-Rosuvastatin · DIN 02438917 · $0.1284
Apo-Rosuvastatin · DIN 02337975 · $0.1284
Auro-Rosuvastatin · DIN 02442574 · $0.1284
Bio-Rosuvastatin · DIN 02444968 · $0.1284
Co Rosuvastatin · DIN 02339765 · $0.1284
Jamp Rosuvastatin Calcium · DIN 02498332 · $0.1284
Jamp-Rosuvastatin · DIN 02391252 · $0.1284
M-Rosuvastatin · DIN 02496534 · $0.1284
Mar-Rosuvastatin · DIN 02413051 · $0.1284
Med-Rosuvastatin · DIN 02399164 · $0.1284
Mint-Rosuvastatin · DIN 02397781 · $0.1284
NRA-Rosuvastatin · DIN 02477483 · $0.1284
NRA-Rosuvastatin Tablets · DIN 02536595 · $0.1284
PMS-Rosuvastatin · DIN 02378523 · $0.1284
PRZ-Rosuvastatin · DIN 02505576 · $0.1284
Rosuvastatin · DIN 02405628 · $0.1284
Rosuvastatin · DIN 02411628 · $0.1284
Sandoz Rosuvastatin · DIN 02338726 · $0.1284
Taro-Rosuvastatin · DIN 02382644 · $0.1284
Teva-Rosuvastatin · DIN 02354608 · $0.1284
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02265540
Shortage record checked October 6, 2026
Jamp Rosuvastatin Calcium · DIN 02498332 · 5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Rosuvastatin Calcium · DIN 02498332
Manufacturer: Jamp Pharma Corporation; listing date 2021-04-30
Health Canada: Marketed since 2025-07-15 · brand JAMP ROSUVASTATIN TABLETS · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 5 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp Rosuvastatin Calcium: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1284). What the ministry pays, not the patient.
Ministry pays: $0.1284 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02498332)
Source record
DIN 02498332: Jamp Rosuvastatin Calcium
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600066; group id 308; item number 0674; lccId None; manufacturer id JPC
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1284; ministry $0.1284
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02498332
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98811
Interchangeable products
Ach-Rosuvastatin · DIN 02438917 · $0.1284
Apo-Rosuvastatin · DIN 02337975 · $0.1284
Auro-Rosuvastatin · DIN 02442574 · $0.1284
Bio-Rosuvastatin · DIN 02444968 · $0.1284
Co Rosuvastatin · DIN 02339765 · $0.1284
Crestor · DIN 02265540 · $0.1284
Jamp-Rosuvastatin · DIN 02391252 · $0.1284
M-Rosuvastatin · DIN 02496534 · $0.1284
Mar-Rosuvastatin · DIN 02413051 · $0.1284
Med-Rosuvastatin · DIN 02399164 · $0.1284
Mint-Rosuvastatin · DIN 02397781 · $0.1284
NRA-Rosuvastatin · DIN 02477483 · $0.1284
NRA-Rosuvastatin Tablets · DIN 02536595 · $0.1284
PMS-Rosuvastatin · DIN 02378523 · $0.1284
PRZ-Rosuvastatin · DIN 02505576 · $0.1284
Rosuvastatin · DIN 02405628 · $0.1284
Rosuvastatin · DIN 02411628 · $0.1284
Sandoz Rosuvastatin · DIN 02338726 · $0.1284
Taro-Rosuvastatin · DIN 02382644 · $0.1284
Teva-Rosuvastatin · DIN 02354608 · $0.1284
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02498332
Shortage record checked October 6, 2026
M-Rosuvastatin · DIN 02496534 · 5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
M-Rosuvastatin · DIN 02496534
Manufacturer: Mantra Pharma Inc.; listing date 2021-10-29
Health Canada: Marketed since 2023-12-21 · brand M-ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 5 MG · company Mantra pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordM-Rosuvastatin: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1284). What the ministry pays, not the patient.
Ministry pays: $0.1284 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02496534)
Source record
DIN 02496534: M-Rosuvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600066; group id 308; item number 0674; lccId None; manufacturer id MAT
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1284; ministry $0.1284
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02496534
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98639
Interchangeable products
Ach-Rosuvastatin · DIN 02438917 · $0.1284
Apo-Rosuvastatin · DIN 02337975 · $0.1284
Auro-Rosuvastatin · DIN 02442574 · $0.1284
Bio-Rosuvastatin · DIN 02444968 · $0.1284
Co Rosuvastatin · DIN 02339765 · $0.1284
Crestor · DIN 02265540 · $0.1284
Jamp Rosuvastatin Calcium · DIN 02498332 · $0.1284
Jamp-Rosuvastatin · DIN 02391252 · $0.1284
Mar-Rosuvastatin · DIN 02413051 · $0.1284
Med-Rosuvastatin · DIN 02399164 · $0.1284
Mint-Rosuvastatin · DIN 02397781 · $0.1284
NRA-Rosuvastatin · DIN 02477483 · $0.1284
NRA-Rosuvastatin Tablets · DIN 02536595 · $0.1284
PMS-Rosuvastatin · DIN 02378523 · $0.1284
PRZ-Rosuvastatin · DIN 02505576 · $0.1284
Rosuvastatin · DIN 02405628 · $0.1284
Rosuvastatin · DIN 02411628 · $0.1284
Sandoz Rosuvastatin · DIN 02338726 · $0.1284
Taro-Rosuvastatin · DIN 02382644 · $0.1284
Teva-Rosuvastatin · DIN 02354608 · $0.1284
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02496534
Shortage record checked October 6, 2026
Mar-Rosuvastatin · DIN 02413051 · 5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mar-Rosuvastatin · DIN 02413051
Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2014-04-01
Health Canada: Marketed since 2023-06-09 · brand MAR-ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 5 MG · company Marcan pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMar-Rosuvastatin: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1284). What the ministry pays, not the patient.
Ministry pays: $0.1284 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02413051)
Source record
DIN 02413051: Mar-Rosuvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600066; group id 308; item number 0674; lccId None; manufacturer id MAR
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1284; ministry $0.1284
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02413051
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89772
Interchangeable products
Ach-Rosuvastatin · DIN 02438917 · $0.1284
Apo-Rosuvastatin · DIN 02337975 · $0.1284
Auro-Rosuvastatin · DIN 02442574 · $0.1284
Bio-Rosuvastatin · DIN 02444968 · $0.1284
Co Rosuvastatin · DIN 02339765 · $0.1284
Crestor · DIN 02265540 · $0.1284
Jamp Rosuvastatin Calcium · DIN 02498332 · $0.1284
Jamp-Rosuvastatin · DIN 02391252 · $0.1284
M-Rosuvastatin · DIN 02496534 · $0.1284
Med-Rosuvastatin · DIN 02399164 · $0.1284
Mint-Rosuvastatin · DIN 02397781 · $0.1284
NRA-Rosuvastatin · DIN 02477483 · $0.1284
NRA-Rosuvastatin Tablets · DIN 02536595 · $0.1284
PMS-Rosuvastatin · DIN 02378523 · $0.1284
PRZ-Rosuvastatin · DIN 02505576 · $0.1284
Rosuvastatin · DIN 02405628 · $0.1284
Rosuvastatin · DIN 02411628 · $0.1284
Sandoz Rosuvastatin · DIN 02338726 · $0.1284
Taro-Rosuvastatin · DIN 02382644 · $0.1284
Teva-Rosuvastatin · DIN 02354608 · $0.1284
Shortage status: resolved shortage (ended November 17, 2020); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02413051
Shortage record checked October 6, 2026
Mint-Rosuvastatin · DIN 02397781 · 5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mint-Rosuvastatin · DIN 02397781
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2013-08-29
Health Canada: Marketed since 2026-06-15 · brand MINT-ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 5 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMint-Rosuvastatin: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1284). What the ministry pays, not the patient.
Ministry pays: $0.1284 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02397781)
Source record
DIN 02397781: Mint-Rosuvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600066; group id 308; item number 0674; lccId None; manufacturer id MIN
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1284; ministry $0.1284
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02397781
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88271
Interchangeable products
Ach-Rosuvastatin · DIN 02438917 · $0.1284
Apo-Rosuvastatin · DIN 02337975 · $0.1284
Auro-Rosuvastatin · DIN 02442574 · $0.1284
Bio-Rosuvastatin · DIN 02444968 · $0.1284
Co Rosuvastatin · DIN 02339765 · $0.1284
Crestor · DIN 02265540 · $0.1284
Jamp Rosuvastatin Calcium · DIN 02498332 · $0.1284
Jamp-Rosuvastatin · DIN 02391252 · $0.1284
M-Rosuvastatin · DIN 02496534 · $0.1284
Mar-Rosuvastatin · DIN 02413051 · $0.1284
Med-Rosuvastatin · DIN 02399164 · $0.1284
NRA-Rosuvastatin · DIN 02477483 · $0.1284
NRA-Rosuvastatin Tablets · DIN 02536595 · $0.1284
PMS-Rosuvastatin · DIN 02378523 · $0.1284
PRZ-Rosuvastatin · DIN 02505576 · $0.1284
Rosuvastatin · DIN 02405628 · $0.1284
Rosuvastatin · DIN 02411628 · $0.1284
Sandoz Rosuvastatin · DIN 02338726 · $0.1284
Taro-Rosuvastatin · DIN 02382644 · $0.1284
Teva-Rosuvastatin · DIN 02354608 · $0.1284
Shortage status: resolved shortage (ended June 15, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02397781
Shortage record checked October 6, 2026
NRA-Rosuvastatin Tablets · DIN 02536595 · 5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
NRA-Rosuvastatin Tablets · DIN 02536595
Manufacturer: Nora Pharma; listing date 2024-01-31
Health Canada: Marketed since 2023-09-14 · brand NRA-ROSUVASTATIN TABLETS · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 5 MG · company Nora pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordNRA-Rosuvastatin Tablets: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1284). What the ministry pays, not the patient.
Ministry pays: $0.1284 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02536595)
Source record
DIN 02536595: NRA-Rosuvastatin Tablets
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600066; group id 308; item number 0674; lccId None; manufacturer id NRA
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1284; ministry $0.1284
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02536595
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102535
Interchangeable products
Ach-Rosuvastatin · DIN 02438917 · $0.1284
Apo-Rosuvastatin · DIN 02337975 · $0.1284
Auro-Rosuvastatin · DIN 02442574 · $0.1284
Bio-Rosuvastatin · DIN 02444968 · $0.1284
Co Rosuvastatin · DIN 02339765 · $0.1284
Crestor · DIN 02265540 · $0.1284
Jamp Rosuvastatin Calcium · DIN 02498332 · $0.1284
Jamp-Rosuvastatin · DIN 02391252 · $0.1284
M-Rosuvastatin · DIN 02496534 · $0.1284
Mar-Rosuvastatin · DIN 02413051 · $0.1284
Med-Rosuvastatin · DIN 02399164 · $0.1284
Mint-Rosuvastatin · DIN 02397781 · $0.1284
NRA-Rosuvastatin · DIN 02477483 · $0.1284
PMS-Rosuvastatin · DIN 02378523 · $0.1284
PRZ-Rosuvastatin · DIN 02505576 · $0.1284
Rosuvastatin · DIN 02405628 · $0.1284
Rosuvastatin · DIN 02411628 · $0.1284
Sandoz Rosuvastatin · DIN 02338726 · $0.1284
Taro-Rosuvastatin · DIN 02382644 · $0.1284
Teva-Rosuvastatin · DIN 02354608 · $0.1284
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02536595
Shortage record checked October 6, 2026
PMS-Rosuvastatin · DIN 02378523 · 5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Rosuvastatin · DIN 02378523
Manufacturer: Pharmascience Inc.; listing date 2012-05-29
Health Canada: Marketed since 2012-03-15 · brand PMS-ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 5 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPMS-Rosuvastatin: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1284). What the ministry pays, not the patient.
Ministry pays: $0.1284 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02378523)
Source record
DIN 02378523: PMS-Rosuvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600066; group id 308; item number 0674; lccId None; manufacturer id PMS
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1284; ministry $0.1284
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02378523
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86432
Interchangeable products
Ach-Rosuvastatin · DIN 02438917 · $0.1284
Apo-Rosuvastatin · DIN 02337975 · $0.1284
Auro-Rosuvastatin · DIN 02442574 · $0.1284
Bio-Rosuvastatin · DIN 02444968 · $0.1284
Co Rosuvastatin · DIN 02339765 · $0.1284
Crestor · DIN 02265540 · $0.1284
Jamp Rosuvastatin Calcium · DIN 02498332 · $0.1284
Jamp-Rosuvastatin · DIN 02391252 · $0.1284
M-Rosuvastatin · DIN 02496534 · $0.1284
Mar-Rosuvastatin · DIN 02413051 · $0.1284
Med-Rosuvastatin · DIN 02399164 · $0.1284
Mint-Rosuvastatin · DIN 02397781 · $0.1284
NRA-Rosuvastatin · DIN 02477483 · $0.1284
NRA-Rosuvastatin Tablets · DIN 02536595 · $0.1284
PRZ-Rosuvastatin · DIN 02505576 · $0.1284
Rosuvastatin · DIN 02405628 · $0.1284
Rosuvastatin · DIN 02411628 · $0.1284
Sandoz Rosuvastatin · DIN 02338726 · $0.1284
Taro-Rosuvastatin · DIN 02382644 · $0.1284
Teva-Rosuvastatin · DIN 02354608 · $0.1284
Shortage status: resolved shortage (ended February 19, 2018); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02378523
Shortage record checked October 6, 2026
PRZ-Rosuvastatin · DIN 02505576 · 5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PRZ-Rosuvastatin · DIN 02505576
Manufacturer: Pharmaris Canada Inc.; listing date 2022-01-31
Health Canada: Marketed since 2021-10-12 · brand PRZ-ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 5 MG · company Pharmaris canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPRZ-Rosuvastatin: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1284). What the ministry pays, not the patient.
Ministry pays: $0.1284 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02505576)
Source record
DIN 02505576: PRZ-Rosuvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600066; group id 308; item number 0674; lccId None; manufacturer id PRZ
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1284; ministry $0.1284
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02505576
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99494
Interchangeable products
Ach-Rosuvastatin · DIN 02438917 · $0.1284
Apo-Rosuvastatin · DIN 02337975 · $0.1284
Auro-Rosuvastatin · DIN 02442574 · $0.1284
Bio-Rosuvastatin · DIN 02444968 · $0.1284
Co Rosuvastatin · DIN 02339765 · $0.1284
Crestor · DIN 02265540 · $0.1284
Jamp Rosuvastatin Calcium · DIN 02498332 · $0.1284
Jamp-Rosuvastatin · DIN 02391252 · $0.1284
M-Rosuvastatin · DIN 02496534 · $0.1284
Mar-Rosuvastatin · DIN 02413051 · $0.1284
Med-Rosuvastatin · DIN 02399164 · $0.1284
Mint-Rosuvastatin · DIN 02397781 · $0.1284
NRA-Rosuvastatin · DIN 02477483 · $0.1284
NRA-Rosuvastatin Tablets · DIN 02536595 · $0.1284
PMS-Rosuvastatin · DIN 02378523 · $0.1284
Rosuvastatin · DIN 02405628 · $0.1284
Rosuvastatin · DIN 02411628 · $0.1284
Sandoz Rosuvastatin · DIN 02338726 · $0.1284
Taro-Rosuvastatin · DIN 02382644 · $0.1284
Teva-Rosuvastatin · DIN 02354608 · $0.1284
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02505576
Shortage record checked October 6, 2026
Rosuvastatin · DIN 02405628 · 5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Rosuvastatin · DIN 02405628
Manufacturer: Sanis Health Inc.; listing date 2016-05-31
Health Canada: Marketed since 2022-09-01 · brand ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 5 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordRosuvastatin: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1284). What the ministry pays, not the patient.
Ministry pays: $0.1284 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02405628)
Source record
DIN 02405628: Rosuvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600066; group id 308; item number 0674; lccId None; manufacturer id SAI
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1284; ministry $0.1284
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02405628
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89039
Interchangeable products
Ach-Rosuvastatin · DIN 02438917 · $0.1284
Apo-Rosuvastatin · DIN 02337975 · $0.1284
Auro-Rosuvastatin · DIN 02442574 · $0.1284
Bio-Rosuvastatin · DIN 02444968 · $0.1284
Co Rosuvastatin · DIN 02339765 · $0.1284
Crestor · DIN 02265540 · $0.1284
Jamp Rosuvastatin Calcium · DIN 02498332 · $0.1284
Jamp-Rosuvastatin · DIN 02391252 · $0.1284
M-Rosuvastatin · DIN 02496534 · $0.1284
Mar-Rosuvastatin · DIN 02413051 · $0.1284
Med-Rosuvastatin · DIN 02399164 · $0.1284
Mint-Rosuvastatin · DIN 02397781 · $0.1284
NRA-Rosuvastatin · DIN 02477483 · $0.1284
NRA-Rosuvastatin Tablets · DIN 02536595 · $0.1284
PMS-Rosuvastatin · DIN 02378523 · $0.1284
PRZ-Rosuvastatin · DIN 02505576 · $0.1284
Rosuvastatin · DIN 02411628 · $0.1284
Sandoz Rosuvastatin · DIN 02338726 · $0.1284
Taro-Rosuvastatin · DIN 02382644 · $0.1284
Teva-Rosuvastatin · DIN 02354608 · $0.1284
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02405628
Shortage record checked October 6, 2026
Rosuvastatin · DIN 02411628 · 5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Rosuvastatin · DIN 02411628
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30
Health Canada: Marketed since 2024-01-12 · brand ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 5 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordRosuvastatin: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1284). What the ministry pays, not the patient.
Ministry pays: $0.1284 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02411628)
Source record
DIN 02411628: Rosuvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600066; group id 308; item number 0674; lccId None; manufacturer id SIV
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1284; ministry $0.1284
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02411628
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89622
Interchangeable products
Ach-Rosuvastatin · DIN 02438917 · $0.1284
Apo-Rosuvastatin · DIN 02337975 · $0.1284
Auro-Rosuvastatin · DIN 02442574 · $0.1284
Bio-Rosuvastatin · DIN 02444968 · $0.1284
Co Rosuvastatin · DIN 02339765 · $0.1284
Crestor · DIN 02265540 · $0.1284
Jamp Rosuvastatin Calcium · DIN 02498332 · $0.1284
Jamp-Rosuvastatin · DIN 02391252 · $0.1284
M-Rosuvastatin · DIN 02496534 · $0.1284
Mar-Rosuvastatin · DIN 02413051 · $0.1284
Med-Rosuvastatin · DIN 02399164 · $0.1284
Mint-Rosuvastatin · DIN 02397781 · $0.1284
NRA-Rosuvastatin · DIN 02477483 · $0.1284
NRA-Rosuvastatin Tablets · DIN 02536595 · $0.1284
PMS-Rosuvastatin · DIN 02378523 · $0.1284
PRZ-Rosuvastatin · DIN 02505576 · $0.1284
Rosuvastatin · DIN 02405628 · $0.1284
Sandoz Rosuvastatin · DIN 02338726 · $0.1284
Taro-Rosuvastatin · DIN 02382644 · $0.1284
Teva-Rosuvastatin · DIN 02354608 · $0.1284
Shortage status: resolved shortage (ended June 7, 2021); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02411628
Shortage record checked October 6, 2026
Sandoz Rosuvastatin · DIN 02338726 · 5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Rosuvastatin · DIN 02338726
Manufacturer: Sandoz Canada Inc.; listing date 2012-05-29
Health Canada: Marketed since 2012-03-15 · brand SANDOZ ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 5 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordSandoz Rosuvastatin: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1284). What the ministry pays, not the patient.
Ministry pays: $0.1284 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02338726)
Source record
DIN 02338726: Sandoz Rosuvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600066; group id 308; item number 0674; lccId None; manufacturer id SDZ
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1284; ministry $0.1284
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02338726
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82437
Interchangeable products
Ach-Rosuvastatin · DIN 02438917 · $0.1284
Apo-Rosuvastatin · DIN 02337975 · $0.1284
Auro-Rosuvastatin · DIN 02442574 · $0.1284
Bio-Rosuvastatin · DIN 02444968 · $0.1284
Co Rosuvastatin · DIN 02339765 · $0.1284
Crestor · DIN 02265540 · $0.1284
Jamp Rosuvastatin Calcium · DIN 02498332 · $0.1284
Jamp-Rosuvastatin · DIN 02391252 · $0.1284
M-Rosuvastatin · DIN 02496534 · $0.1284
Mar-Rosuvastatin · DIN 02413051 · $0.1284
Med-Rosuvastatin · DIN 02399164 · $0.1284
Mint-Rosuvastatin · DIN 02397781 · $0.1284
NRA-Rosuvastatin · DIN 02477483 · $0.1284
NRA-Rosuvastatin Tablets · DIN 02536595 · $0.1284
PMS-Rosuvastatin · DIN 02378523 · $0.1284
PRZ-Rosuvastatin · DIN 02505576 · $0.1284
Rosuvastatin · DIN 02405628 · $0.1284
Rosuvastatin · DIN 02411628 · $0.1284
Taro-Rosuvastatin · DIN 02382644 · $0.1284
Teva-Rosuvastatin · DIN 02354608 · $0.1284
Shortage status: resolved shortage (ended May 13, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02338726
Shortage record checked October 6, 2026
Taro-Rosuvastatin · DIN 02382644 · 5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Taro-Rosuvastatin · DIN 02382644
Manufacturer: Sun Pharma; listing date 2012-05-29
Health Canada: Marketed since 2020-03-01 · brand TARO-ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 5 MG · company Sun pharma canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTaro-Rosuvastatin: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1284). What the ministry pays, not the patient.
Ministry pays: $0.1284 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02382644)
Source record
DIN 02382644: Taro-Rosuvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600066; group id 308; item number 0674; lccId None; manufacturer id SPC
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1284; ministry $0.1284
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02382644
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86846
Interchangeable products
Ach-Rosuvastatin · DIN 02438917 · $0.1284
Apo-Rosuvastatin · DIN 02337975 · $0.1284
Auro-Rosuvastatin · DIN 02442574 · $0.1284
Bio-Rosuvastatin · DIN 02444968 · $0.1284
Co Rosuvastatin · DIN 02339765 · $0.1284
Crestor · DIN 02265540 · $0.1284
Jamp Rosuvastatin Calcium · DIN 02498332 · $0.1284
Jamp-Rosuvastatin · DIN 02391252 · $0.1284
M-Rosuvastatin · DIN 02496534 · $0.1284
Mar-Rosuvastatin · DIN 02413051 · $0.1284
Med-Rosuvastatin · DIN 02399164 · $0.1284
Mint-Rosuvastatin · DIN 02397781 · $0.1284
NRA-Rosuvastatin · DIN 02477483 · $0.1284
NRA-Rosuvastatin Tablets · DIN 02536595 · $0.1284
PMS-Rosuvastatin · DIN 02378523 · $0.1284
PRZ-Rosuvastatin · DIN 02505576 · $0.1284
Rosuvastatin · DIN 02405628 · $0.1284
Rosuvastatin · DIN 02411628 · $0.1284
Sandoz Rosuvastatin · DIN 02338726 · $0.1284
Teva-Rosuvastatin · DIN 02354608 · $0.1284
Shortage status: resolved shortage (ended January 2, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02382644
Shortage record checked October 6, 2026
Teva-Rosuvastatin · DIN 02354608 · 5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Rosuvastatin · DIN 02354608
Manufacturer: Teva Canada Limited; listing date 2012-05-29
Health Canada: Marketed since 2012-03-15 · brand TEVA-ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 5 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTeva-Rosuvastatin: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1284). What the ministry pays, not the patient.
Ministry pays: $0.1284 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02354608)
Source record
DIN 02354608: Teva-Rosuvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600066; group id 308; item number 0674; lccId None; manufacturer id TEV
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1284; ministry $0.1284
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02354608
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83977
Interchangeable products
Ach-Rosuvastatin · DIN 02438917 · $0.1284
Apo-Rosuvastatin · DIN 02337975 · $0.1284
Auro-Rosuvastatin · DIN 02442574 · $0.1284
Bio-Rosuvastatin · DIN 02444968 · $0.1284
Co Rosuvastatin · DIN 02339765 · $0.1284
Crestor · DIN 02265540 · $0.1284
Jamp Rosuvastatin Calcium · DIN 02498332 · $0.1284
Jamp-Rosuvastatin · DIN 02391252 · $0.1284
M-Rosuvastatin · DIN 02496534 · $0.1284
Mar-Rosuvastatin · DIN 02413051 · $0.1284
Med-Rosuvastatin · DIN 02399164 · $0.1284
Mint-Rosuvastatin · DIN 02397781 · $0.1284
NRA-Rosuvastatin · DIN 02477483 · $0.1284
NRA-Rosuvastatin Tablets · DIN 02536595 · $0.1284
PMS-Rosuvastatin · DIN 02378523 · $0.1284
PRZ-Rosuvastatin · DIN 02505576 · $0.1284
Rosuvastatin · DIN 02405628 · $0.1284
Rosuvastatin · DIN 02411628 · $0.1284
Sandoz Rosuvastatin · DIN 02338726 · $0.1284
Taro-Rosuvastatin · DIN 02382644 · $0.1284
Shortage status: resolved shortage (ended June 3, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02354608
Shortage record checked October 6, 2026
Ach-Rosuvastatin · DIN 02438925 · 10 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ach-Rosuvastatin · DIN 02438925
Manufacturer: Accord Healthcare Inc.; listing date 2019-07-31
Health Canada: Marketed since 2019-05-23 · brand ACH-ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 10 MG · company Accord healthcare inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAch-Rosuvastatin: Formulary list price $0.14 per unit (the source does not state the unit; exact figure $0.1354). What the ministry pays, not the patient.
Ministry pays: $0.1354 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02438925)
Source record
DIN 02438925: Ach-Rosuvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600044; group id 308; item number 0675; lccId None; manufacturer id ACH
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1354; ministry $0.1354
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02438925
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92330
Interchangeable products
Apo-Rosuvastatin · DIN 02337983 · $0.1354
Auro-Rosuvastatin · DIN 02442582 · $0.1354
Bio-Rosuvastatin · DIN 02444976 · $0.1354
Co Rosuvastatin · DIN 02339773 · $0.1354
Crestor · DIN 02247162 · $0.1354
Jamp Rosuvastatin Calcium · DIN 02498340 · $0.1354
Jamp-Rosuvastatin · DIN 02391260 · $0.1354
M-Rosuvastatin · DIN 02496542 · $0.1354
Mar-Rosuvastatin · DIN 02413078 · $0.1354
Med-Rosuvastatin · DIN 02399172 · $0.1354
Mint-Rosuvastatin · DIN 02397803 · $0.1354
NRA-Rosuvastatin · DIN 02477491 · $0.1354
NRA-Rosuvastatin Tablets · DIN 02536609 · $0.1354
PMS-Rosuvastatin · DIN 02378531 · $0.1354
PRZ-Rosuvastatin · DIN 02505584 · $0.1354
Rosuvastatin · DIN 02405636 · $0.1354
Rosuvastatin · DIN 02411636 · $0.1354
Sandoz Rosuvastatin · DIN 02338734 · $0.1354
Taro-Rosuvastatin · DIN 02382652 · $0.1354
Teva-Rosuvastatin · DIN 02354616 · $0.1354
Shortage status: resolved shortage (ended September 6, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02438925
Shortage record checked October 6, 2026
Apo-Rosuvastatin · DIN 02337983 · 10 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Rosuvastatin · DIN 02337983
Manufacturer: Apotex Inc.; listing date 2012-05-29
Health Canada: Marketed since 2012-04-02 · brand APO-ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 10 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Rosuvastatin: Formulary list price $0.14 per unit (the source does not state the unit; exact figure $0.1354). What the ministry pays, not the patient.
Ministry pays: $0.1354 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02337983)
Source record
DIN 02337983: Apo-Rosuvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600044; group id 308; item number 0675; lccId None; manufacturer id APX
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1354; ministry $0.1354
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02337983
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82363
Interchangeable products
Ach-Rosuvastatin · DIN 02438925 · $0.1354
Auro-Rosuvastatin · DIN 02442582 · $0.1354
Bio-Rosuvastatin · DIN 02444976 · $0.1354
Co Rosuvastatin · DIN 02339773 · $0.1354
Crestor · DIN 02247162 · $0.1354
Jamp Rosuvastatin Calcium · DIN 02498340 · $0.1354
Jamp-Rosuvastatin · DIN 02391260 · $0.1354
M-Rosuvastatin · DIN 02496542 · $0.1354
Mar-Rosuvastatin · DIN 02413078 · $0.1354
Med-Rosuvastatin · DIN 02399172 · $0.1354
Mint-Rosuvastatin · DIN 02397803 · $0.1354
NRA-Rosuvastatin · DIN 02477491 · $0.1354
NRA-Rosuvastatin Tablets · DIN 02536609 · $0.1354
PMS-Rosuvastatin · DIN 02378531 · $0.1354
PRZ-Rosuvastatin · DIN 02505584 · $0.1354
Rosuvastatin · DIN 02405636 · $0.1354
Rosuvastatin · DIN 02411636 · $0.1354
Sandoz Rosuvastatin · DIN 02338734 · $0.1354
Taro-Rosuvastatin · DIN 02382652 · $0.1354
Teva-Rosuvastatin · DIN 02354616 · $0.1354
Shortage status: resolved shortage (ended December 11, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02337983
Shortage record checked October 6, 2026
Auro-Rosuvastatin · DIN 02442582 · 10 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Rosuvastatin · DIN 02442582
Manufacturer: Auro Pharma Inc.; listing date 2016-04-01
Health Canada: Marketed since 2015-11-30 · brand AURO-ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 10 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAuro-Rosuvastatin: Formulary list price $0.14 per unit (the source does not state the unit; exact figure $0.1354). What the ministry pays, not the patient.
Ministry pays: $0.1354 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02442582)
Source record
DIN 02442582: Auro-Rosuvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600044; group id 308; item number 0675; lccId None; manufacturer id AUR
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1354; ministry $0.1354
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02442582
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92692
Interchangeable products
Ach-Rosuvastatin · DIN 02438925 · $0.1354
Apo-Rosuvastatin · DIN 02337983 · $0.1354
Bio-Rosuvastatin · DIN 02444976 · $0.1354
Co Rosuvastatin · DIN 02339773 · $0.1354
Crestor · DIN 02247162 · $0.1354
Jamp Rosuvastatin Calcium · DIN 02498340 · $0.1354
Jamp-Rosuvastatin · DIN 02391260 · $0.1354
M-Rosuvastatin · DIN 02496542 · $0.1354
Mar-Rosuvastatin · DIN 02413078 · $0.1354
Med-Rosuvastatin · DIN 02399172 · $0.1354
Mint-Rosuvastatin · DIN 02397803 · $0.1354
NRA-Rosuvastatin · DIN 02477491 · $0.1354
NRA-Rosuvastatin Tablets · DIN 02536609 · $0.1354
PMS-Rosuvastatin · DIN 02378531 · $0.1354
PRZ-Rosuvastatin · DIN 02505584 · $0.1354
Rosuvastatin · DIN 02405636 · $0.1354
Rosuvastatin · DIN 02411636 · $0.1354
Sandoz Rosuvastatin · DIN 02338734 · $0.1354
Taro-Rosuvastatin · DIN 02382652 · $0.1354
Teva-Rosuvastatin · DIN 02354616 · $0.1354
Shortage status: resolved shortage (ended June 30, 2021); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02442582
Shortage record checked October 6, 2026
Bio-Rosuvastatin · DIN 02444976 · 10 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Bio-Rosuvastatin · DIN 02444976
Manufacturer: Biomed Pharma; listing date 2026-09-29
Health Canada: Marketed since 2021-08-11 · brand BIO-ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 10 MG · company Biomed pharma · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordBio-Rosuvastatin: Formulary list price $0.14 per unit (the source does not state the unit; exact figure $0.1354). What the ministry pays, not the patient.
Ministry pays: $0.1354 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02444976)
Source record
DIN 02444976: Bio-Rosuvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600044; group id 308; item number 0675; lccId None; manufacturer id BMP
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1354; ministry $0.1354
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02444976
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93019
Interchangeable products
Ach-Rosuvastatin · DIN 02438925 · $0.1354
Apo-Rosuvastatin · DIN 02337983 · $0.1354
Auro-Rosuvastatin · DIN 02442582 · $0.1354
Co Rosuvastatin · DIN 02339773 · $0.1354
Crestor · DIN 02247162 · $0.1354
Jamp Rosuvastatin Calcium · DIN 02498340 · $0.1354
Jamp-Rosuvastatin · DIN 02391260 · $0.1354
M-Rosuvastatin · DIN 02496542 · $0.1354
Mar-Rosuvastatin · DIN 02413078 · $0.1354
Med-Rosuvastatin · DIN 02399172 · $0.1354
Mint-Rosuvastatin · DIN 02397803 · $0.1354
NRA-Rosuvastatin · DIN 02477491 · $0.1354
NRA-Rosuvastatin Tablets · DIN 02536609 · $0.1354
PMS-Rosuvastatin · DIN 02378531 · $0.1354
PRZ-Rosuvastatin · DIN 02505584 · $0.1354
Rosuvastatin · DIN 02405636 · $0.1354
Rosuvastatin · DIN 02411636 · $0.1354
Sandoz Rosuvastatin · DIN 02338734 · $0.1354
Taro-Rosuvastatin · DIN 02382652 · $0.1354
Teva-Rosuvastatin · DIN 02354616 · $0.1354
Shortage status: resolved shortage (ended January 30, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02444976
Shortage record checked October 6, 2026
Crestor · DIN 02247162 · 10 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Savings card: innoviCares lists Crestor (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up.
(innovicares.ca ↗)Savings card: RxHelp ONE lists CRESTOR (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim.
(rxhelp.ca ↗)Limit of one Prescription Drug Card Program / Patient Financial Assistance Card from any adjudicator per DIN and claim submitted. The RxHelpONE card CANNOT be combined with any other card or offer. (Terms of Use)
(rxhelp.ca, September 10, 2026 ↗)1 brand, same coverage
Crestor · DIN 02247162
Manufacturer: AstraZeneca; listing date 2003-09-04
Health Canada: Marketed since 2003-02-19 · brand CRESTOR - 10MG · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 10 MG · company Astrazeneca canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMinistry pays: $0.1354 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02247162)
Source record
DIN 02247162: Crestor
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600044; group id 308; item number 0675; lccId None; manufacturer id AZC
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.6117; ministry $0.1354
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02247162
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71404
Interchangeable products
Ach-Rosuvastatin · DIN 02438925 · $0.1354
Apo-Rosuvastatin · DIN 02337983 · $0.1354
Auro-Rosuvastatin · DIN 02442582 · $0.1354
Bio-Rosuvastatin · DIN 02444976 · $0.1354
Co Rosuvastatin · DIN 02339773 · $0.1354
Jamp Rosuvastatin Calcium · DIN 02498340 · $0.1354
Jamp-Rosuvastatin · DIN 02391260 · $0.1354
M-Rosuvastatin · DIN 02496542 · $0.1354
Mar-Rosuvastatin · DIN 02413078 · $0.1354
Med-Rosuvastatin · DIN 02399172 · $0.1354
Mint-Rosuvastatin · DIN 02397803 · $0.1354
NRA-Rosuvastatin · DIN 02477491 · $0.1354
NRA-Rosuvastatin Tablets · DIN 02536609 · $0.1354
PMS-Rosuvastatin · DIN 02378531 · $0.1354
PRZ-Rosuvastatin · DIN 02505584 · $0.1354
Rosuvastatin · DIN 02405636 · $0.1354
Rosuvastatin · DIN 02411636 · $0.1354
Sandoz Rosuvastatin · DIN 02338734 · $0.1354
Taro-Rosuvastatin · DIN 02382652 · $0.1354
Teva-Rosuvastatin · DIN 02354616 · $0.1354
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02247162
Shortage record checked October 6, 2026
Jamp Rosuvastatin Calcium · DIN 02498340 · 10 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Rosuvastatin Calcium · DIN 02498340
Manufacturer: Jamp Pharma Corporation; listing date 2021-04-30
Health Canada: Marketed since 2025-07-16 · brand JAMP ROSUVASTATIN TABLETS · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 10 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp Rosuvastatin Calcium: Formulary list price $0.14 per unit (the source does not state the unit; exact figure $0.1354). What the ministry pays, not the patient.
Ministry pays: $0.1354 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02498340)
Source record
DIN 02498340: Jamp Rosuvastatin Calcium
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600044; group id 308; item number 0675; lccId None; manufacturer id JPC
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1354; ministry $0.1354
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02498340
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98812
Interchangeable products
Ach-Rosuvastatin · DIN 02438925 · $0.1354
Apo-Rosuvastatin · DIN 02337983 · $0.1354
Auro-Rosuvastatin · DIN 02442582 · $0.1354
Bio-Rosuvastatin · DIN 02444976 · $0.1354
Co Rosuvastatin · DIN 02339773 · $0.1354
Crestor · DIN 02247162 · $0.1354
Jamp-Rosuvastatin · DIN 02391260 · $0.1354
M-Rosuvastatin · DIN 02496542 · $0.1354
Mar-Rosuvastatin · DIN 02413078 · $0.1354
Med-Rosuvastatin · DIN 02399172 · $0.1354
Mint-Rosuvastatin · DIN 02397803 · $0.1354
NRA-Rosuvastatin · DIN 02477491 · $0.1354
NRA-Rosuvastatin Tablets · DIN 02536609 · $0.1354
PMS-Rosuvastatin · DIN 02378531 · $0.1354
PRZ-Rosuvastatin · DIN 02505584 · $0.1354
Rosuvastatin · DIN 02405636 · $0.1354
Rosuvastatin · DIN 02411636 · $0.1354
Sandoz Rosuvastatin · DIN 02338734 · $0.1354
Taro-Rosuvastatin · DIN 02382652 · $0.1354
Teva-Rosuvastatin · DIN 02354616 · $0.1354
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02498340
Shortage record checked October 6, 2026
M-Rosuvastatin · DIN 02496542 · 10 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
M-Rosuvastatin · DIN 02496542
Manufacturer: Mantra Pharma Inc.; listing date 2021-10-29
Health Canada: Marketed since 2024-02-28 · brand M-ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 10 MG · company Mantra pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordM-Rosuvastatin: Formulary list price $0.14 per unit (the source does not state the unit; exact figure $0.1354). What the ministry pays, not the patient.
Ministry pays: $0.1354 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02496542)
Source record
DIN 02496542: M-Rosuvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600044; group id 308; item number 0675; lccId None; manufacturer id MAT
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1354; ministry $0.1354
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02496542
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98640
Interchangeable products
Ach-Rosuvastatin · DIN 02438925 · $0.1354
Apo-Rosuvastatin · DIN 02337983 · $0.1354
Auro-Rosuvastatin · DIN 02442582 · $0.1354
Bio-Rosuvastatin · DIN 02444976 · $0.1354
Co Rosuvastatin · DIN 02339773 · $0.1354
Crestor · DIN 02247162 · $0.1354
Jamp Rosuvastatin Calcium · DIN 02498340 · $0.1354
Jamp-Rosuvastatin · DIN 02391260 · $0.1354
Mar-Rosuvastatin · DIN 02413078 · $0.1354
Med-Rosuvastatin · DIN 02399172 · $0.1354
Mint-Rosuvastatin · DIN 02397803 · $0.1354
NRA-Rosuvastatin · DIN 02477491 · $0.1354
NRA-Rosuvastatin Tablets · DIN 02536609 · $0.1354
PMS-Rosuvastatin · DIN 02378531 · $0.1354
PRZ-Rosuvastatin · DIN 02505584 · $0.1354
Rosuvastatin · DIN 02405636 · $0.1354
Rosuvastatin · DIN 02411636 · $0.1354
Sandoz Rosuvastatin · DIN 02338734 · $0.1354
Taro-Rosuvastatin · DIN 02382652 · $0.1354
Teva-Rosuvastatin · DIN 02354616 · $0.1354
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02496542
Shortage record checked October 6, 2026
Other products in the same Health Canada class (C10A, C10AA): coverage varies; not interchangeable
- Atorvastatin (Lipitor): general benefit
- Fluvastatin (Lescol): general benefit, not a benefit
- Lovastatin (Mevacor): general benefit, not a benefit
- Pravastatin (Pravachol): general benefit, not a benefit
- Simvastatin (Zocor): general benefit, not a benefit
- Bezafibrate (Bezalip): general benefit
9 more in the class list below